The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Identifying patients with NTRK fusion cancer
Open accessAbstract
Due to the efficacy of tropomyosin receptor kinase (TRK) inhibitor therapy and the recent Food and Drug Administration approval of larotrectinib, it is now clinically important to accurately and efficiently identify patients with neurotrophic TRK (NTRK) fusion-driven cancer. These oncogenic fusions occur when the kinase domain of NTRK1, NTRK2 or NTRK3 fuse with any of a number of N-terminal partners. NTRK fusions are characteristic of a few rare types of cancer, such as secretory carcinoma of the breast or salivary gland and infantile fibrosarcoma, but they are also infrequently seen in some common cancers, such as melanoma, glioma and carcinomas of the thyroid, lung and colon. There are multiple methods for identifying NTRK fusions, including pan-TRK immunohistochemistry, fluorescence in situ hybridisation and sequencing methods, and the advantages and drawbacks of each are reviewed here. While testing algorithms will obviously depend on availability of various testing modalities and economic considerations for each individual laboratory, we propose triaging specimens based on histology and other molecular findings to most efficiently identify tumours harbouring these treatable oncogenic fusions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Zehir, A., Benayed, R., Shah, R. H., Syed, A., Middha, S., Kim, H. R., Srinivasan, P., Gao, J., Chakravarty, D., Devlin, S. M., et al. (2017) · Nature Medicine · doi:10.1038/nm.4333 · Cited by 3,380 · cited 2×
“because of the aforementioned issues involving coverage of the NTRK3 introns, fusions involving NTRK3 other than ETV6, are not covered by the assay [25, 28, 37].”
BackgroundSelf-citationEfficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children
Drilon, A., Laetsch, T. W., Kummar, S., DuBois, S. G., Lassen, U. N., Demetri, G. D., Nathenson, M., Doebele, R. C., Farago, A. F., Pappo, A. S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1714448 · Cited by 2,824
Self-citationNTRK fusion-positive cancers and TRK inhibitor therapy
Cocco, E., Scaltriti, M., & Drilon, A. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0113-0 · Cited by 1,485
Kaplan, D. R., Martin-Zanca, D., & Parada, L. F. (1991) · Nature · doi:10.1038/350158a0 · Cited by 1,055
Skálová, A., Vanecek, T., Sima, R., Laco, J., Weinreb, I., Perez-Ordonez, B., Starek, I., Geierova, M., Simpson, R. H., Passador-Santos, F., et al. (2010) · American Journal of Surgical Pathology · doi:10.1097/pas.0b013e3181d9efcc · Cited by 1,023
Anchored multiplex PCR for targeted next-generation sequencing
Zheng, Z., Liebers, M., Zhelyazkova, B., Cao, Y., Panditi, D., Lynch, K. D., Chen, J., Robinson, H. E., Shim, H. S., Chmielecki, J., et al. (2014) · Nature Medicine · doi:10.1038/nm.3729 · Cited by 915
Drilon, A., Siena, S., Ou, S.-H. I., Patel, M., Ahn, M. J., Lee, J., Bauer, T. M., Farago, A. F., Wheler, J. J., Liu, S. V., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-1237 · Cited by 826
Soppet, D., Escandon, E., Maragos, J., Middlemas, D. S., Raid, S. W., Blair, J., Burton, L. E., Stanton, B. R., Kaplan, D. R., Hunter, T., et al. (1991) · Cell · doi:10.1016/0092-8674(91)90396-g · Cited by 820
A human oncogene formed by the fusion of truncated tropomyosin and protein tyrosine kinase sequences
Martin-Zanca, D., Hughes, S. H., & Barbacid, M. (1986) · Nature · doi:10.1038/319743a0 · Cited by 803
A novel ETV6-NTRK3 gene fusion in congenital fibrosarcoma
Knezevich, S. R., McFadden, D. E., Tao, W., Lim, J. F., & Sorensen, P. H. B. (1998) · Nature Genetics · doi:10.1038/ng0298-184 · Cited by 800
TRKing Down an Old Oncogene in a New Era of Targeted Therapy
Vaishnavi, A., Le, A. T., & Doebele, R. C. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0765 · Cited by 642
NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls
Solomon, J. P., Linkov, I., Rosado, A., Mullaney, K., Rosen, E. Y., Frosina, D., Jungbluth, A. A., Zehir, A., Benayed, R., Drilon, A., et al. (2020) · Modern Pathology · doi:10.1038/s41379-019-0324-7 · Cited by 546
Self-citationMolecular characterization of cancers with NTRK gene fusions
Gatalica, Z., Xiu, J., Swensen, J., & Vranic, S. (2019) · Modern Pathology · doi:10.1038/s41379-018-0118-3 · Cited by 486
Benayed, R., Offin, M., Mullaney, K., Sukhadia, P., Rios, K., Desmeules, P., Ptashkin, R., Won, H., Chang, J., Halpenny, D., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0225 · Cited by 484
Self-citationPan-Trk Immunohistochemistry Is an Efficient and Reliable Screen for the Detection of NTRK Fusions
Hechtman, J. F., Benayed, R., Hyman, D. M., Drilon, A., Zehir, A., Frosina, D., Arcila, M. E., Dogan, S., Klimstra, D. S., Ladanyi, M., et al. (2017) · American Journal of Surgical Pathology · doi:10.1097/pas.0000000000000911 · Cited by 468
Self-citationDrilon, A., Nagasubramanian, R., Blake, J. F., Ku, N., Tuch, B. B., Ebata, K., Smith, S., Lauriault, V., Kolakowski, G. R., Brandhuber, B. J., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0507 · Cited by 439
Self-citationDoebele, R. C., Davis, L. E., Vaishnavi, A., Le, A. T., Estrada-Bernal, A., Keysar, S., Jimeno, A., Varella-Garcia, M., Aisner, D. L., Li, Y., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0443 · Cited by 388
Marchiò, C., Scaltriti, M., Ladanyi, M., Iafrate, A. J., Bibeau, F., Dietel, M., Hechtman, J. F., Troiani, T., López-Rios, F., Douillard, J.-Y., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz204 · Cited by 372
Self-citationWang, L., Motoi, T., Khanin, R., Olshen, A., Mertens, F., Bridge, J., Cin, P. D., Antonescu, C. R., Singer, S., Hameed, M., et al. (2012) · Genes, Chromosomes and Cancer · doi:10.1002/gcc.20937 · Cited by 347
Self-citationBourgeois, J. M., Knezevich, S. R., Mathers, J. A., & Sorensen, P. H. B. (2000) · The American Journal of Surgical Pathology · doi:10.1097/00000478-200007000-00005 · Cited by 338
ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer
Pietrantonio, F., Di Nicolantonio, F., Schrock, A. B., Lee, J., Tejpar, S., Sartore-Bianchi, A., Hechtman, J. F., Christiansen, J., Novara, L., Tebbutt, N., et al. (2017) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djx089 · Cited by 317
Self-citationAcquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer
Russo, M., Misale, S., Wei, G., Siravegna, G., Crisafulli, G., Lazzari, L., Corti, G., Rospo, G., Novara, L., Mussolin, B., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0940 · Cited by 308
Drilon, A., Li, G., Dogan, S., Gounder, M., Shen, R., Arcila, M., Wang, L., Hyman, D. M., Hechtman, J., Wei, G., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw042 · Cited by 306
Self-citationNTRK Fusions Define a Novel Uterine Sarcoma Subtype With Features of Fibrosarcoma
Chiang, S., Cotzia, P., Hyman, D. M., Drilon, A., Tap, W. D., Zhang, L., Hechtman, J. F., Frosina, D., Jungbluth, A. A., Murali, R., et al. (2018) · American Journal of Surgical Pathology · doi:10.1097/pas.0000000000001055 · Cited by 242
Self-citationIdentification of kinase fusion oncogenes in post-Chernobyl radiation-induced thyroid cancers
Ricarte-Filho, J. C., Li, S., Garcia-Rendueles, M. E. R., Montero-Conde, C., Voza, F., Knauf, J. A., Heguy, A., Viale, A., Bogdanova, T., Thomas, G. A., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci69766 · Cited by 241
Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer
Farago, A. F., Le, L. P., Zheng, Z., Muzikansky, A., Drilon, A., Patel, M., Bauer, T. M., Liu, S. V., Ou, S.-H. I., Jackman, D., et al. (2015) · Journal of Thoracic Oncology · doi:10.1097/01.jto.0000473485.38553.f0 · Cited by 229
Hsiao, S. J., Zehir, A., Sireci, A. N., & Aisner, D. L. (2019) · The Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2019.03.008 · Cited by 226
Clinicopathologic Features of Non–Small-Cell Lung Cancer Harboring an NTRK Gene Fusion
Farago, A. F., Taylor, M. S., Doebele, R. C., Zhu, V. W., Kummar, S., Spira, A. I., Boyle, T. A., Haura, E. B., Arcila, M. E., Benayed, R., et al. (2018) · JCO Precision Oncology · doi:10.1200/po.18.00037 · Cited by 222
Self-citationResistance to TRK inhibition mediated by convergent MAPK pathway activation
Cocco, E., Schram, A. M., Kulick, A., Misale, S., Won, H. H., Yaeger, R., Razavi, P., Ptashkin, R., Hechtman, J. F., Toska, E., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0542-z · Cited by 217
Self-citationPan-Trk Immunohistochemistry Identifies NTRK Rearrangements in Pediatric Mesenchymal Tumors
Rudzinski, E. R., Lockwood, C. M., Stohr, B. A., Vargas, S. O., Sheridan, R., Black, J. O., Rajaram, V., Laetsch, T. W., & Davis, J. L. (2018) · American Journal of Surgical Pathology · doi:10.1097/pas.0000000000001062 · Cited by 213
Skálová, A., Vanecek, T., Simpson, R. H. W., Laco, J., Majewska, H., Baneckova, M., Steiner, P., & Michal, M. (2016) · American Journal of Surgical Pathology · doi:10.1097/pas.0000000000000537 · Cited by 193
Suehara, Y., Arcila, M., Wang, L., Hasanovic, A., Ang, D., Ito, T., Kimura, Y., Drilon, A., Guha, U., Rusch, V., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0838 · Cited by 180
Self-citationInhibiting TRK Proteins in Clinical Cancer Therapy
Lange, A., & Lo, H.-W. (2018) · Cancers · doi:10.3390/cancers10040105 · Cited by 175
Zhu, G., Benayed, R., Ho, C., Mullaney, K., Sukhadia, P., Rios, K., Berry, R., Rubin, B. P., Nafa, K., Wang, L., et al. (2019) · Modern Pathology · doi:10.1038/s41379-018-0175-7 · Cited by 163
Self-citationCocco, E., Benhamida, J., Middha, S., Zehir, A., Mullaney, K., Shia, J., Yaeger, R., Zhang, L., Wong, D., Villafania, L., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-3126 · Cited by 163
Self-citationHung, Y. P., Fletcher, C. D. M., & Hornick, J. L. (2018) · Histopathology · doi:10.1111/his.13666 · Cited by 162
Basket Trials in Oncology: A Trade-Off Between Complexity and Efficiency
Cunanan, K. M., Gönen, M., Shen, R., Hyman, D. M., Riely, G. J., Begg, C. B., & Iasonos, A. E. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.69.9751 · Cited by 136
Neurotrophin-4/5 is a mammalian-specific survival factor for distinct populations of sensory neurons
Davies, A. M., Horton, A. R., Burton, L., Schmelzer, C. H., Vandlen, R. A., & Rosenthal, A. (1993) · Journal of Neuroscience · doi:10.1523/jneurosci.13-11-04961.1993 · Cited by 118
Targetable Gene Fusions Associate With the IDH Wild-Type Astrocytic Lineage in Adult Gliomas
Ferguson, S. D., Zhou, S., Huse, J. T., de Groot, J., Xiu, J., Subramaniam, D. S., Mehta, S. V., Gatalica, Z., Swensen, J. J., Sanai, N., et al. (2018) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nly022 · Cited by 106
Primary and Metastatic Melanoma With NTRK Fusions
Lezcano, C. M., Shoushtari, A. N., Ariyan, C. E., Hollmann, T. J., & BUSAM, K. J. (2018) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000001070 · Cited by 101
Vasudev, P., & Onuma, K. (2011) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2010-0351-rs · Cited by 100
Murphy, D. A., Ely, H. A., Shoemaker, R., Boomer, A., Culver, B. P., Hoskins, I., Haimes, J. D., Walters, R. D., Fernandez, D., Stahl, J. A., et al. (2016) · Applied immunohistochemistry & molecular morphology · doi:10.1097/pai.0000000000000360 · Cited by 85
A Multiplexed Amplicon Approach for Detecting Gene Fusions by Next-Generation Sequencing
Beadling, C., Wald, A. I., Warrick, A., Neff, T. L., Zhong, S., Nikiforov, Y. E., Corless, C. L., & Nikiforova, M. N. (2015) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2015.10.002 · Cited by 79
Validation of a Targeted RNA Sequencing Assay for Kinase Fusion Detection in Solid Tumors
Reeser, J. W., Patacsil, D., Miya, J., Kautto, E. A., Lyon, E., Zhu, E. Y., Wing, M. R., Smith, A. M., Reeder, M., Samorodnitsky, E., et al. (2017) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2017.05.006 · Cited by 78
Gene Fusion in Malignant Glioma: An Emerging Target for Next-Generation Personalized Treatment
Xu, T., Wang, H., Huang, X., Li, W., Huang, Q., Yan, Y., & Chen, J. (2018) · Translational Oncology · doi:10.1016/j.tranon.2018.02.020 · Cited by 60
Identification of NTRK3 Fusions in Childhood Melanocytic Neoplasms
Wang, L., BUSAM, K. J., Benayed, R., Cimera, R., Wang, J., Denley, R. C., Rao, M., Aryeequaye, R., Mullaney, K. A., Cao, L., et al. (2017) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2016.11.005 · Cited by 43
Self-citationMilione, M., Ardini, E., Christiansen, J., Valtorta, E., Veronese, S. M., Bosotti, R., Pellegrinelli, A., Testi, A., Pietrantonio, F., Fucà, G., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.19512 · Cited by 34
Cited by
Update on Fundamental Mechanisms of Thyroid Cancer
Prete, A., Borges de Souza, P., Censi, S., Muzza, M., Nucci, N., & Sponziello, M. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00102 · Cited by 471
Management of Salivary Gland Malignancy: ASCO Guideline
Geiger, J. L., Ismaila, N., Beadle, B., Caudell, J. J., Chau, N., Deschler, D., Glastonbury, C., Kaufman, M., Lamarre, E., Lau, H. Y., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.00449 · Cited by 441
Chakravarty, D., Johnson, A., Sklar, J., Lindeman, N. I., Moore, K., Ganesan, S., Lovly, C. M., Perlmutter, J., Gray, S. W., Hwang, J., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02767 · Cited by 266
Gupta, R., Dittmeier, M., Wohlleben, G., Nickl, V., Bischler, T., Luzak, V., Wegat, V., Doll, D., Sodmann, A., Bady, E., et al. (2024) · Cancer Gene Therapy · doi:10.1038/s41417-024-00809-0 · Cited by 7
“Furthermore, immunohistochemistry of NTRK-positive tumor samples localized NTRK fusion proteins to other cellular compartments than native Trk receptors [38].”
Metadata
- Authors
- Solomon, J. P., Benayed, R., Hechtman, J. F., & Ladanyi, M.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2019-11
- Volume
- 30
- Issue
- Suppl_8
- Pages
- viii16-viii22
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W2988542587
- Cited by
- 270
- References
- 47
- FWCI
- 9.61
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.